TargetMol

GLPG0259

Product Code:
 
TAR-T27416
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27416-5mg5mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27416-50mg50mg£1,982.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27416-100mg100mg£2,560.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
GLPG-0259 is an inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5).
CAS:
959754-85-9
Formula:
C24H28N8O2
Molecular Weight:
460.542
Purity:
0.98
SMILES:
CC(C)(C)N1CCN(CC1)c1ccc(Nc2ncc(-c3coc(c3)C(N)=O)n3ncnc23)cc1

References

1. Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17. PubMed PMID: 23161899. 2. Namour F, Vanhoutte FP, Beetens J, Blockhuys S, De Weer M, Wigerinck P. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects. Drugs R D. 2012 Sep 1;12(3):141-63. doi: 10.2165/11633120-000000000-00000. PubMed PMID: 22950522; PubMed Central PMCID: PMC3585965.